Physician profile
Varinder Kumar
NPI 1225040637
$1,779.21
in general payments reported to CMS, 2019-2025
16 companies · $737 in 2025
The $737 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $120 · 2021: $67.54 · 2022: $260 · 2023: $66.74 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.64 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $689.73 | 2019-2025 | |
| Ucb, INC. | $252.74 | 2019-2025 | Bimzelx |
| Abbvie INC. | $211.46 | 2019-2025 | |
| Amgen INC. | $125.11 | 2019-2025 | Evenity, Krystexxa |
| Glaxosmithkline, LLC. | $116.45 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.77 | 2019-2025 | |
| Pfizer INC. | $47.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $43.25 | 2025 | Enhertu |
| Lilly USA, LLC | $40.96 | 2020-2021 | |
| Abbott Laboratories | $36.40 | 2025 | Cardiomems |
| Radius Health, INC. | $33.85 | 2019 | |
| Genentech USA, INC. | $21.69 | 2019 | |
| Janssen Biotech, INC. | $17.08 | 2021 | |
| Sandoz INC. | $17.05 | 2025 | Jubbonti |
| Sobi, INC | $15.48 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varinder Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.